Advances in Oral GLP-1 Analogs for Obesity: Market Insights, Challenges, and Delivery Strategies

Obesity is a significant global health challenge, necessitating both lifestyle changes and effective pharmacological treatments. By enhancing insulin secretion, inhibiting glucagon release, and promoting feelings of fullness, GLP-1 analogs have emerged as promising obesity therapies. Oral formulations like oral semaglutide represent a groundbreaking advancement in obesity treatment, offering improved patient adherence and expanding the therapeutic market. However, the successful implementation of oral GLP-1 analogs faces obstacles such as ensuring stability and optimizing bioavailability for effective delivery.

This webinar explores the critical role of oral GLP-1 analogs in addressing obesity, highlighting their potential impact on both patient outcomes and the healthcare market, while also examining challenges in formulation and delivery, and the innovative strategies needed to overcome these challenges.